Brought to you by 
Valeant acquires US rights to Eisai's Targretin
26 Feb 2013
Executive Summary
Eisai Co. Ltd.’s US subsidiary Eisai Inc. has granted Valeant Pharmaceuticals International Inc. exclusive US rights to Targretin (bexarotene) capsules and gel 1% for $65mm up front plus potential milestones.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Valeant acquires US rights to Eisai's Targretin
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice